Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 mg GA Depot in Subjects With RRMS
A phase II study of laquinimod in Crohn's disease.
Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
[The influence of locomotor treatment using robotic body-weight-supported treadmill training on rehabilitation outcome of patients suffering from neurological disorders].
Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient.
CHMP assessment report for Sovrima (International nonproprietary name: idebenone)
Pharmaceutical approval update.
Effect of High-Dose Intravenous Methyl-prednisolone Treatment on Intraocular Pressure in Multiple Sclerosis Patients with Relapse.
A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JC virus testing.
Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone.
Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.
FDA warns about seizures linked to MS drug
Confounding in association studies: month of birth and multiple sclerosis.
3D models of human ERα and ERβ complexed with coumestrol.
Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Opposing Effects of Membrane-Anchored CX3CL1 on Amyloid and Tau Pathologies via the p38 MAPK Pathway.
Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic.
Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis.
Metabolic features of the cell danger response.
Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.

Pages